Applicant : West et al.
 Attorney's Docket No.: 22380-014US1

 Serial No.: 10/551,203
 Associate's Reference No.: DAB/RS/P63379JUS

Filed : June 29, 2006 Page : 2 of 12

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application.

Listing of Claims:

1. (Original) An alkaloid formulation comprising the reaction product of one or more

alkaloids with one or more phosphate derivatives of one or more electron transfer agents.

2. (Currently amended) The alkaloid formulation according to claim 1 of claim 1.

wherein the <u>one or more</u> phosphate derivative of a electron transfer agent is selected from the group comprising one or more phosphate derivatives derivatives is a phosphate derivative of

tocopherol.

3. (Currently amended) The alkaloid formulation according to elaim 1 of claim 1,

wherein the formulation is a topical formulation.

4. (Currently amended) The alkaloid formulation according to claim 1 of claim 1,

wherein the formulation is an oral formulation.

(Currently amended) The alkaloid formulation according to claim 4 of claim 4.

further comprising an enteric coating.

(Currently amended) The alkaloid formulation according to claim 4 of claim 4.

wherein the formulation is selected from the group consisting of tablets, powders, chewable

tablets, capsules, oral suspensions, suspensions, emulsions or fluids, children's formulations,

enteral feeds, nutraceuticals, and functional foods.

 Applicant : West et al.
 Attorney's Docket No. : 22380-014US1

 Secial No. : 10/581.203
 Associate's Reference No.: DAB/RS:P63379.US

Filed : June 29, 2006 Page : 3 of 12

 (Currently amended) The alkaloid formulation according to claim 1 of claim 1, wherein the formulation is a buccal formulation.

- 8. (Currently amended) The alkaloid formulation according to claim 1 of claim 1, wherein the electron transfer agent is selected from the group consisting of hydroxyl chromans including alpha, beta, gamma and delpha tocols in enantiomeric and racemic forms; quinols being the reduced forms of vitamin K1 and ubiquinone; hydroxy carotenoids including retinol; calciferol; ascorbic acid and mixtures thereof.
- (Currently amended) The alkaloid formulation aecording to claim 8 of claim 8, wherein the electron transfer agent is selected from the group consisting of tocopherol and other tocols, retinol, vitamin K1 and mixtures thereof.
- 10. (Currently amended) The alkaloid formulation according to claim 9 of claim 9, wherein the electron transfer agent is selected from the group consisting of the tocols and mixtures thereof.
- (Currently amended) The alkaloid formulation according to claim 10 of claim 10, wherein the electron transfer agent is α-tocopherol.
- 12. (Currently amended) The alkaloid formulation according to claim 11 of claim 11, wherein the one or more phosphate derivatives of one or more electron transfer agents is selected from the group consisting of mono-tocopherol phosphate; di-tocopherol phosphate; and mixtures thereof.
- 13. (Currently amended) The alkaloid formulation according to claim 12, wherein the one or more phosphate derivatives of one or more electron transfer agents is a mixture of mono-tocopherol phosphate and di-tocopherol phosphate.

 Applicant : West et al.
 Attorney's Docket No.: 22380-014US1

 Serial No.: 10/551,263
 Associate's Reference No.: DAB/RS:P63379.US

Filed : June 29, 2006 Page : 4 of 12

14. (Currently amended) The alkaloid formulation according to claim 1 of claim 1, wherein the one or more phosphate derivatives of one or more electron transfer agents is a phosphatide.

- 15. (Currently amended) The alkaloid formulation according to claim 1 of claim 1, wherein the alkaloid is one or more alkaloids are selected from the group consisting of tertiary amines which are alicyclic with the nitrogen atom as a common member of three rings; are cyclic where the nitrogen is incorporated into a single ring and alkylated; or have no cyclic structure incorporating the nitrogen; and mixtures thereof.
- 16. (Currently amended) The alkaloid formulation according to claim 15 of claim 15, wherein the alkaloid is one or more alkaloids are selected from the group consisting of atropine, quinine, opioids, fentanyl, nicotine, fenspiride, flurazepan and codeine.
- (Currently amended) The alkaloid formulation according to claim 1 of claim 1, wherein the alkaloid is one or more alkaloids is the alkaloid atropine.
- (Currently amended) The alkaloid formulation according to claim 1, wherein the alkaloid is one or more alkaloids is the alkaloid morphine.

19-20. (Canceled)

- (Original) A pharmaceutical composition comprising the reaction product of one or more alkaloids with one or more phosphate derivatives of one or more electron transfer agents.
- (Currently amended) A <u>The</u> pharmaceutical composition aecording to elaim 21 of claim 21, wherein the electron transfer agent is tocopherol.

 Applicant
 West et al.
 Attorney's Docket No.; 22380-014181

 Serial No.
 10/551,203
 Associate's Reference No.; DAB/RS:P63379.US

Filed : June 29, 2006 Page : 5 of 12

23. (New) The alkaloid formulation of claim 8, wherein the hydroxyl chromans is an alpha, beta, gamma or delta tocol present in enantiomeric or racemic forms.

24. (New) The alkaloid formulation of claim 8, wherein the hydroxy carotenoid is a retinol.